Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives

被引:47
作者
Harries, Anthony D. [1 ,2 ]
Zachariah, Rony [3 ]
van Oosterhout, Joep J. [4 ]
Reid, Steven D. [5 ]
Hosseinipour, Mina C. [6 ]
Arendt, Vic [7 ]
Chirwa, Zengani [8 ,9 ]
Jahn, Andreas [8 ,9 ]
Schouten, Erik J. [8 ,10 ]
Kamoto, Kelita [8 ]
机构
[1] Int Union TB & Lung Dis, Paris, France
[2] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England
[3] Brussels Operat Ctr, Operat Res Unit, Luxembourg, Luxembourg
[4] Coll Med, Dept Med, Blantyre, Malawi
[5] Univ London Imperial Coll Sci Technol & Med, Fac Med, Initiat CD4, London, England
[6] Univ N Carolina Project, Lilongwe, Malawi
[7] Ctr Hosp Luxembourg, Dept Infect Dis, Luxembourg, Luxembourg
[8] Minist Hlth, HIV Dept, Lilongwe, Malawi
[9] Int Training & Educ Ctr, Seattle, WA USA
[10] BASICS, Management Sci Hlth, Lilongwe, Malawi
关键词
DRUG-RESISTANCE MUTATIONS; PUBLIC-HEALTH APPROACH; CD4 CELL COUNTS; HIV-INFECTION; VIRAL LOAD; HIV-1-INFECTED ADULTS; VIROLOGICAL FAILURE; SCALING-UP; OUTCOMES; MALAWI;
D O I
10.1016/S1473-3099(09)70321-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Despite the enormous progress made in scaling up antiretroviral therapy (ART) in sub-Saharan Africa, many challenges remain, not least of which are the identification and management of patients who have failed first-line therapy. Less than 3% of patients are receiving second-line treatment at present, whereas 15-25% of patients have detectable viral loads 12 months or more into treatment, of whom a substantial proportion might have virological failure. We discuss the reasons why virological ART failure is likely to be under-diagnosed in the routine health system, and address the current difficulties with standard recommended second-line ART regimens. The development of new diagnostic tools for ART failure, in particular a point-of-care HIV viral-load test, combined with simple and inexpensive second-line therapy, such as boosted protease-inhibitor monotherapy, could revolutionise the management of ART failure in resource-limited settings.
引用
收藏
页码:60 / 65
页数:6
相关论文
共 59 条
[1]   Lessons learned from use of highly active antiretroviral therapy in Africa [J].
Akileswaran, C ;
Lurie, MN ;
Flanigan, TP ;
Mayer, KH .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (03) :376-385
[2]  
[Anonymous], 2009, Progress Report'
[3]  
[Anonymous], NAT EST HIV AIDS MAL
[4]  
ARRIBAS J, 2009, P 5 C HIV PATH TREAT
[5]   Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting [J].
Badri, Motasim ;
Lawn, Stephen D. ;
Wood, Robin .
BMC INFECTIOUS DISEASES, 2008, 8 (1)
[6]   HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review [J].
Bierman, Wouter F. W. ;
van Agtmael, Michiel A. ;
Nijhuis, Monique ;
Danner, Sven A. ;
Boucher, Charles A. B. .
AIDS, 2009, 23 (03) :279-291
[7]   Antiretroviral therapy and early morality in South Africa [J].
Boulle, Andrew ;
Bock, Peter ;
Osler, Meg ;
Cohen, Karen ;
Channing, Liezl ;
Hilderbrand, Katherine ;
Mothibi, Eula ;
Zweigenthal, Virginia ;
Slingers, Neviline ;
Cloete, Keith ;
Abdullah, Fareed .
BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2008, 86 (09) :678-687
[8]   Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy [J].
Boulle, Andrew ;
Van Cutsem, Gilles ;
Cohen, Karen ;
Hilderbrand, Katherine ;
Mathee, Shaheed ;
Abrahams, Musaed ;
Goemaere, Eric ;
Coetzee, David ;
Maartens, Gary .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (05) :530-539
[9]  
Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2
[10]   A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries [J].
Colebunders, R ;
Moses, KR ;
Laurence, J ;
Shihab, HM ;
Semitala, F ;
Lutwama, F ;
Bakeera-Kitaka, S ;
Lynen, L ;
Spacek, L ;
Reynolds, SJ ;
Quinn, TC ;
Viner, B ;
Mayanja-Kizza, H .
LANCET INFECTIOUS DISEASES, 2006, 6 (01) :53-59